Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Vaccine Development Agreements Target Encephalitis Bioterror Agent

By SRI International | April 28, 2017

SRI International awarded $4.7 million in agreements to manufacture and test vaccine against Venezuelan equine encephalitis.

SRI International has been awarded two agreements worth $4.7 million to manufacture and conduct clinical testing on a potential new vaccine against Venezuelan equine encephalitis (VEE), a serious viral infection for which there is currently no commercially available vaccine. 

The VEE virus (VEEV) is a type of alphavirus that typically causes mild to severe influenza-like symptoms, but can progress to serious neurological complications such as insomnia, seizures, confusion, and coma. Young adults, who are in the typical age ranges of U.S. warfighters, are more likely to develop serious and potentially deadly VEEV complications, including encephalitis.

Military service members can be exposed to VEEV when deployed to regions where the virus is endemic (e.g., Central and South America), or where aerosolized VEEV could be used as a biological weapon.

The Centers for Disease Control has classified VEEV as a category B bioterror agent.  Previous VEEV vaccines had issues with tolerability and failed to stimulate adequate levels of protective antibodies against VEEV in studies of aerosolized VEEV exposure. 

“We are honored by the opportunity to help our military develop a vaccine with better safety, tolerability, and efficacy than previous VEEV vaccines,” said George Hughes, Jr., M.D., FACP, physician investigator, SRI Biosciences, and principal investigator for the clinical study.

Under the agreement, sponsored by the United States Army’s Joint Vaccine Acquisition Program (JVAP), SRI will manufacture the vaccine in its Good Manufacturing Practice (GMP) certified production facility in Menlo Park, Calif. and test the novel compound in a Phase 1 study at SRI’s Clinical Trials Unit (CTU) in Plymouth, Mich.  SRI will also assist in submitting the Investigational New Drug application to enable human clinical trials. 

“We will apply SRI’s extensive clinical manufacturing and research expertise to provide this vaccine and then determine a safe and effective dose for individuals who may be exposed to aerosolized VEEV,” said Jia-Hwa Fang, director of Clinical Manufacturing, SRI Biosciences. “Successful manufacture and clinical testing of this vaccine could also advance efforts against other types of alphaviruses.”

Once the vaccine product is developed, researchers at SRI’s CTU will conduct a dose-escalation, safety, tolerance, and immunogenicity study of the virus-like particle (VLP) vaccine in 90 healthy adult volunteers. SRI’s 9,200 square-foot CTU in the Michigan Life Science and Innovation Center facility includes an investigational pharmacy, a sample-processing laboratory, and amenities to accommodate extended overnight stays for research participants. 

Recruitment for healthy adult volunteers will begin in Q3 2017.

(Source: PR Newswire)


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE